ARS Pharmaceuticals, Inc. financial data

Symbol
SPRY on Nasdaq
Location
11682 El Camino Real, Suite 120, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 853 % -71.7%
Quick Ratio 41.6 %
Debt-to-equity 65.3 % +1828%
Return On Equity -38.8 % -71.9%
Return On Assets -23.5 % -7.52%
Operating Margin -63.6 % +97.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98.8M shares +1.71%
Common Stock, Shares, Outstanding 98.8M shares +1.75%
Entity Public Float 466M USD +22.1%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 98.8M shares +1.83%
Weighted Average Number of Shares Outstanding, Diluted 98.8M shares +1.83%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 143M USD +5460%
Research and Development Expense 12.8M USD -36%
General and Administrative Expense 38.7M USD -1.14%
Operating Income (Loss) -90.8M USD -50%
Net Income (Loss) Attributable to Parent -80M USD -63%
Earnings Per Share, Basic 0 USD/shares -58.8%
Earnings Per Share, Diluted 0 USD/shares -58.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.6M USD +50.2%
Accounts Receivable, after Allowance for Credit Loss, Current 36.5M USD +4616%
Inventory, Net 21.4M USD +2897%
Assets, Current 339M USD +62.3%
Property, Plant and Equipment, Net 1.21M USD +43.4%
Operating Lease, Right-of-Use Asset 1.44M USD +1464%
Intangible Assets, Net (Excluding Goodwill) 14.7M USD +96.4%
Other Assets, Noncurrent 690K USD
Assets 373M USD +71.3%
Accounts Payable, Current 8.38M USD +1.28%
Employee-related Liabilities, Current 5.45M USD
Contract with Customer, Liability, Current 526K USD
Liabilities, Current 50.9M USD +206%
Contract with Customer, Liability, Noncurrent 1.27M USD
Operating Lease, Liability, Noncurrent 949K USD
Liabilities 225M USD +1254%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7K USD -102%
Retained Earnings (Accumulated Deficit) -253M USD -46.2%
Stockholders' Equity Attributable to Parent 148M USD -26.5%
Liabilities and Equity 373M USD +71.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.7M USD -507%
Net Cash Provided by (Used in) Financing Activities 725K USD +181%
Net Cash Provided by (Used in) Investing Activities 29.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 98.8M shares +1.75%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11M USD +26.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.6M USD +50.2%
Deferred Tax Assets, Valuation Allowance 36.9M USD +26.9%
Deferred Tax Assets, Gross 36.9M USD +26.9%
Operating Lease, Liability 1.53M USD +1402%
Depreciation 11K USD -45%
Payments to Acquire Property, Plant, and Equipment 91K USD +9.64%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80.4M USD -65.4%
Lessee, Operating Lease, Liability, to be Paid 1.85M USD +1683%
Property, Plant and Equipment, Gross 748K USD +14.7%
Operating Lease, Liability, Current 583K USD +472%
Lessee, Operating Lease, Liability, to be Paid, Year Two 627K USD +1393%
Lessee, Operating Lease, Liability, to be Paid, Year One 609K USD +882%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 322K USD +16000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 318K USD
Deferred Tax Assets, Operating Loss Carryforwards 12.8M USD -20.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.03M USD +139%
Operating Lease, Payments 141K USD +127%
Additional Paid in Capital 401M USD +7.24%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 300 USD
Deferred Tax Assets, Net of Valuation Allowance 37M USD +26.9%
Share-based Payment Arrangement, Expense 14.5M USD +57.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%